Draft synthesis: glucagon-like peptide-1 receptor agonists… — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. A single-trial result is presented in the visual form of a pooled estimate — arising from DRAFT-GLP1-OBESITY/012. Outcomes contributed by a single trial are now reported without a pooled diamond, labelled as unreplicated, and downgraded for imprecision or inconsistency according to the framework rather than presented as a synthesis.
2. The review protocol is described but its registration record is not linked — arising from DRAFT-GLP1-OBESITY/005. Each synthesis now links its own protocol with the version in force at screening, and states explicitly where an external registration identifier is not held, so that the absence is a recorded fact.
3. References should carry a persistent identifier for every cited source — arising from DRAFT-GLP1-OBESITY/008. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
4. The same concern is used to downgrade in two domains — arising from DRAFT-GLP1-OBESITY/003. The rating for the first outcome has been raised by one level and the domain reasoning restated, and the reasoning for the second has been rewritten to make clear that the two downgrades rest on different features of the evidence.
5. Doses differing several-fold are pooled without examining dose-response — arising from DRAFT-GLP1-OBESITY/013. Estimates are now reported by dose group, a dose-response examination is reported where three or more dose levels contribute, and the pooled across-dose estimate is removed rather than retained alongside.
6. Two included studies do not meet the registered eligibility criteria — arising from DRAFT-GLP1-OBESITY/014. One study has been removed from the included set and the estimate recomputed, the exclusion reason for the third study has been corrected in the excluded-studies table, and the screening decisions are now recorded against the protocol version in force at the…
7. Risk-of-bias judgements are reported as an overall rating without the domains — arising from DRAFT-GLP1-OBESITY/009. Risk of bias is now reported at domain level for every included study, with the text on which each judgement was based quoted and referenced, and the overall judgement derived from the domains rather than asserted alongside them.
8. Regulatory assessment documents were not searched — arising from DRAFT-GLP1-OBESITY/004. Published regulatory assessment documents are now searched as a named source, are reported as a distinct evidence class in the included-studies table, and contribute to the assessment while being excluded from pooled estimates where risk of bias could not be…
9. Point estimates are given without an interval — arising from DRAFT-GLP1-OBESITY/001. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
10. The conclusion is stated more strongly than the certainty rating supports — arising from DRAFT-GLP1-OBESITY/015. Conclusion wording is now drawn from a fixed set of formulations tied to the certainty rating, so that a low certainty rating produces a statement that the evidence may suggest an effect and that the estimate is likely to change with further research.
11. Subgroup findings are reported that were not registered in the protocol — arising from DRAFT-GLP1-OBESITY/007. Every subgroup analysis is now labelled as pre-specified or post hoc against the registered protocol, post hoc analyses are reported in a separate subsection without a certainty rating, and the protocol version against which the labelling was made is stated.
12. Patient-reported outcomes are collected by the trials and not reported by the review — arising from DRAFT-GLP1-OBESITY/002. Patient-reported outcomes measured by any contributing trial are now reported narratively by instrument, with the instrument named and its minimum important difference stated where one is published, and the absence of a pooled estimate explained.
13. Registered trials that never reported are not counted anywhere in the review — arising from DRAFT-GLP1-OBESITY/010. Registered trials without posted results are now identified, counted and reported as a distinct category in the screening flow, with the proportion of registered participants they represent stated in the limitations.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.